ACCUTANE

ACCUTANE is a widely prescribed medication for severe (recalcitrant cystic) acne that is unresponsive to standard treatment. Mounting evidence indicates that there are serious problems with ACCUTANE.

Tragic Side Effects
Developed by Hoffman La Roche, and approved by the FDA in 1982, the association between ACCUTANE and increased risks of depression, suicide, and birth defects are well established.

Uninformed Victims & Over Prescribed
In 1998, Hoffman La Roche was directed by the FDA to add “Bold Face Warnings” to ACCUTANE’s physician package inserts. These warning were designed to alert physicians and patients to the drugs potential to trigger depression, psychosis, and suicidal thoughts. Some families claim that their physicians never warned them of these potential side effects.
While ACCUTANE was designed only to treat the severest forms of acne, studies have shown that it may be over-prescribed to patients, who do no need such strong medication.

Acute Physical Side Effects
Additional studies have also revealed possible links to inflammatory bowel disease—BS and Chrohn’s disease—Lupus, liver damage, and colon cancer. If you or a loved one have taken ACCUTANE and developed any of the following medical conditions during or after the course of treatment, you may be entitled to substantial monetary compensation:

Inflammatory Bowel Disease Crohn’s Disease Ulcerative Colitis Rectal Bleeding Liver Damage Pancreatitis Lupus

Kidney Damage Depression Psychosis Suicide / Attempted Suicide Birth Defects Immune System Impairment

Taking legal action against a drug manufacturer for injuries caused by pharmaceuticals, the usual standards of product liability apply: strict liability, negligence, and breach of warranty. If a physician's conduct is to blame, a medical malpractice suit may be justified.

Levy Phillips & Konigsberg, LLP, has won complex litigation verdicts with large settlements. The firm offers experienced, aggressive representation for ACCUTANE victims and their families.

For more information call 212.605.6200 or email

Alan J. Konigsberg